BRPI0518132A - e2-epf5, uma inusitada proteìna e alvo terapêutico - Google Patents
e2-epf5, uma inusitada proteìna e alvo terapêuticoInfo
- Publication number
- BRPI0518132A BRPI0518132A BRPI0518132-1A BRPI0518132A BRPI0518132A BR PI0518132 A BRPI0518132 A BR PI0518132A BR PI0518132 A BRPI0518132 A BR PI0518132A BR PI0518132 A BRPI0518132 A BR PI0518132A
- Authority
- BR
- Brazil
- Prior art keywords
- epf5
- vegf
- therapeutic
- provides
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61890704P | 2004-10-14 | 2004-10-14 | |
PCT/US2005/036505 WO2006044366A2 (en) | 2004-10-14 | 2005-10-12 | E2-epf5, a novel therapeutic protein and target |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518132A true BRPI0518132A (pt) | 2008-10-28 |
Family
ID=36203455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518132-1A BRPI0518132A (pt) | 2004-10-14 | 2005-10-12 | e2-epf5, uma inusitada proteìna e alvo terapêutico |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1802343A2 (ru) |
JP (1) | JP2008516953A (ru) |
KR (1) | KR20070083640A (ru) |
CN (1) | CN101039694A (ru) |
AU (1) | AU2005295863A1 (ru) |
BR (1) | BRPI0518132A (ru) |
CA (1) | CA2580883A1 (ru) |
RU (1) | RU2007117771A (ru) |
WO (1) | WO2006044366A2 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100877824B1 (ko) * | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2epf ucp-vhl 상호작용 및 그 용도 |
US9066976B2 (en) | 2005-11-11 | 2015-06-30 | Korea Research Institute Of Bioscience And Biotechnology | Method for therapeutic angiogenesis |
CN102618545B (zh) * | 2006-06-09 | 2014-12-10 | 株式会社益力多本社 | 与人癌细胞的永生化相关的基因及其应用 |
ITMI20101030A1 (it) * | 2010-06-09 | 2011-12-10 | Sergio Capaccioli | Uso di oligonucleotidi antisenso per il trattamento di degenerazioni e neoplasie retiniche |
CN114621346A (zh) * | 2013-08-21 | 2022-06-14 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
JP5990308B1 (ja) * | 2015-08-05 | 2016-09-14 | 和英 宮本 | 人工合成疑似e3を有効成分とする、疾患診断を補助する方法および装置、それを用いた疾患診断キットおよびそれを用いた抗癌剤選択支援方法 |
CN111228502A (zh) * | 2020-03-10 | 2020-06-05 | 新疆医科大学第三附属医院 | 人ube2s基因的用途及相关产品 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5384255A (en) * | 1993-06-21 | 1995-01-24 | Rappaport Family Institute For Research In The Medical Sciences | Ubiquitin carrier enzyme E2-F1, purification, production, and use |
US20030232436A1 (en) * | 2002-06-14 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of E2-EPF expression |
-
2005
- 2005-10-12 AU AU2005295863A patent/AU2005295863A1/en not_active Abandoned
- 2005-10-12 JP JP2007536798A patent/JP2008516953A/ja active Pending
- 2005-10-12 KR KR1020077008125A patent/KR20070083640A/ko not_active Application Discontinuation
- 2005-10-12 EP EP05810594A patent/EP1802343A2/en not_active Withdrawn
- 2005-10-12 RU RU2007117771/14A patent/RU2007117771A/ru not_active Application Discontinuation
- 2005-10-12 CN CNA2005800353498A patent/CN101039694A/zh active Pending
- 2005-10-12 CA CA002580883A patent/CA2580883A1/en not_active Abandoned
- 2005-10-12 WO PCT/US2005/036505 patent/WO2006044366A2/en active Application Filing
- 2005-10-12 BR BRPI0518132-1A patent/BRPI0518132A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070083640A (ko) | 2007-08-24 |
RU2007117771A (ru) | 2008-11-27 |
CN101039694A (zh) | 2007-09-19 |
WO2006044366A2 (en) | 2006-04-27 |
JP2008516953A (ja) | 2008-05-22 |
CA2580883A1 (en) | 2006-04-27 |
EP1802343A2 (en) | 2007-07-04 |
AU2005295863A1 (en) | 2006-04-27 |
WO2006044366A3 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schmidlin et al. | Redox regulation by NRF2 in aging and disease | |
Meeran et al. | Cell cycle control as a basis for cancer chemoprevention through dietary agents | |
BRPI0518132A (pt) | e2-epf5, uma inusitada proteìna e alvo terapêutico | |
Thakur et al. | APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions | |
Jäger et al. | The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress | |
Parsons et al. | The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SH-SY5Y neuroblastoma cells against the toxicity of Complex I inhibitors | |
Saraiva et al. | Amyloid-β triggers the release of neuronal hexokinase 1 from mitochondria | |
Croce et al. | NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection? | |
Kim et al. | The role of p300 histone acetyltransferase in UV-induced histone modifications and MMP-1 gene transcription | |
Kalani et al. | Epigenetic impact of curcumin on stroke prevention | |
Shalaby et al. | SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs | |
NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
NI201000033A (es) | Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis | |
IS8343A (is) | Próteasómtálmar og aðferðir til að nota þá | |
BRPI0511350A (pt) | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto | |
Luo et al. | Andrographolide inhibits the activation of NF‑κB and MMP‑9 activity in H3255 lung cancer cells | |
Gu et al. | Therapeutic effect of resveratrol on mice with depression | |
Pandian et al. | Development of programmable small DNA-binding molecules with epigenetic activity for induction of core pluripotency genes | |
Lu et al. | Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors | |
Nalivaeva et al. | New insights into epigenetic and pharmacological regulation of amyloid-degrading enzymes | |
Toma et al. | Where environment meets cognition: a focus on two developmental intellectual disability disorders | |
Tsai et al. | The role of heat shock protein 70 in the protective effect of YC-1 on β-amyloid-induced toxicity in differentiated PC12 cells | |
Tian et al. | The neuroprotective mechanism of puerarin in the treatment of acute spinal ischemia–reperfusion injury is linked to cyclin-dependent kinase 5 | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
Deng et al. | Amyloid-beta peptide neurotoxicity in human neuronal cells is associated with modulation of insulin-like growth factor transport, lysosomal machinery and extracellular matrix receptor interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |